ABOS

Acumen is a clinical-stage, pre-revenue biopharma whose entire value rests on one asset: sabirnetug, an anti-amyloid-beta-oligomer antibody in the Phase 2 ALTITUDE-AD trial, with top-line results due late 2026. There is no product, no revenue line in any year FY2021-FY2025, and a five-year string of losses (-$121M in FY2025, a -172% return on equity). This is a pure binary bet on a single Alzheimer's readout in a field littered with high-profile failures — the definition of unknowable risk for a self-directed retail investor.

The balance sheet makes the risk acute. Cash and equivalents are just $54.0M against operating cash burn of -$116M in FY2025 (which itself worsened 34% YoY) — well under a year of runway heading into a catalyst that is still 12-18 months out. Current assets of $122M offer some cushion, but stockholders' equity collapsed 61% to $70.4M, total assets fell 49%, and management explicitly flags 'Liquidity, Capital Resources and Going Concern' in the MD&A. A raise before the data is close to inevitable, and shares already grew 19% in a year; expect further heavy dilution at a depressed ~$2.74 price, plus a K2HV/loan covenant that bars dividends and adds a small debt claim ($22.4M long-term + $8.77M current) ahead of equity.